The Clearant Process® can dramatically reduce the risk of infection in biological therapeutic products by inactivating all known types of human pathogens while preserving the structure and integrity of the tissue. Unlike other available techniques, the Clearant Process® completely penetrates tissues and can be applied to products in their final shipping container.
"Human tissue implants can offer patients substantial benefits in terms of increased mobility and range of motion with minimal healing times," said John Lee, Executive Director of DCI Donor Services. "By integrating the Clearant Process into our programs, DCI Donor Services can continue to offer high quality tissue for transplantation."
Initially, DCI Donor Services will have a limited range of Clearant Process® treated musculoskeletal implants, with a full range of products expected to be becoming available later this year.
"Patient safety is the number one priority for Clearant and the tissue allograft industry," said Clearant's Chief Operating Officer Alain Delongchamp. "By offering Clearant treated human tissue allografts, DCI Donor Services is leading the field in developing implant technology for the new millennium."
About DCI Donor Services
DCI Donor Services (DCIDS) is an affiliation of organ and tissue recovery organizations across the United States that are dedicated to providing organs and tissues for transplantation. The mission of DCI Donor Services is to support families in member communities who have sustained the loss of a loved one by providing an opportunity for the donation of anatomical gifts and by facilitating the recovery and transplantation of these gifts to individuals in need. DCIDS Tissue Services currently recovers and processes tissue from approximately 1,000 donors annually, resulting in the processing of approximately 25,000 transplant allografts. Additionally, they provide tissue to researchers within their recovery service area to promote the advancement of scientific investigation and medical therapy.
About Clearant, Inc.
Clearant, Inc., a biotechnology company headquartered in Los Angeles, California, is a leader in pathogen inactivation for biological products. Clearant® has developed the patent protected Clearant Process®, designed to substantially reduce all known types of pathogens in biological products while preserving a high degree of the underlying protein. Various sterilization methods on the market today kill only specific types of pathogens, such as bacteria or lipid-enveloped viruses, for specific products. The Clearant Process® can substantially reduce all known types of pathogens for products across many market segments including plasma proteins, tissue implants, recombinant products and blood products, and can be applied at various stages of product processing/manufacturing, including in the final container.
The company's revenue includes fees from licensing its patented technology and research and development fees generated on projects for commercial customers and government grants. The Clearant Process® is marketed through a direct sales force primarily in the United States and in Europe.
For more information about Clearant, Inc., the Clearant Process®, microbial sterilization and viral inactivation please see www.clearant.com.